Efimosfermin for Fatty Liver Disease

(NEBULA-2 Trial)

This trial tests the safety and effectiveness of a new treatment called efimosfermin alfa for individuals with compensated cirrhosis due to MASH, a type of fatty liver disease. In the first part, some participants will receive the treatment, while others will receive a placebo (inactive substance). Those who complete the first part and qualify can join the second part, where everyone receives the treatment. Individuals with metabolic syndrome—a cluster of conditions like high blood pressure, high blood sugar, or abnormal cholesterol levels—and diagnosed with liver cirrhosis might be suitable for this trial. As a Phase 3 trial, this study represents the final step before FDA approval, offering participants a chance to contribute to a potentially groundbreaking treatment.

Research has shown that efimosfermin alfa is generally safe for humans. Studies have found that people tolerate it well. For instance, earlier trials reported significant reductions in liver fat, indicating the treatment is both effective and safe. Additionally, results demonstrate a positive safety profile for patients with a type of liver disease called MASH, with improvements in liver health. Overall, the data supports the safety of efimosfermin alfa, with no major side effects reported.¹²³⁴⁵

Most treatments for fatty liver disease, such as lifestyle modifications and medications aimed at reducing liver fat, don't directly target the underlying mechanisms of the disease. Efimosfermin alfa stands out because it is designed to specifically target and improve liver function by potentially reducing fat accumulation and inflammation in the liver. Researchers are excited about this treatment due to its novel mechanism of action, which might offer a more direct and effective approach to combating fatty liver disease compared to current options.

Research has shown that efimosfermin alfa may help treat fatty liver disease. Studies have found it can significantly reduce liver fat and improve liver health. In one study, all participants experienced a reduction in liver fat. Another study demonstrated that it helped reduce liver scarring and swelling, which are crucial for preventing the progression of liver disease. Additionally, 89% of patients saw major improvements in their liver condition. In this trial, participants in Part A will receive either efimosfermin alfa or a placebo, while in Part B, all participants will receive efimosfermin alfa. This evidence suggests that efimosfermin alfa could be effective for managing fatty liver disease.¹²³⁴⁵